Microbiome Connect: Gut Therapeutics USA, a two-day conference from the 17th – 18th of November 2021 and will bring you essential solutions to the challenges you face in the microbiome field. This industry-leading event will facilitate discussions concerning new clinical research, microbiome biomarkers, the latest regulatory developments, gut-organ axis, human clinical updates and much more. Hear from experts like Bernat Olle, CEO of Vedanta Bioscience, regarding the state of the market post-C Diff. therapy approval, and Diwakar Davar, to discuss his ground-breaking immuno-oncology research.

The event will have dedicated manufacturing steam; attendees will witness a showcase of solutions to scaling up your bacterial fermentation operation, highlighting the different culturing methodologies along with discussions regarding commercialization preparation. Joined by companies such as Takeda, Merck, and PRI, who will discuss the microbiome’s clinical future as a diagnostic and endpoint and examine how the industry can and should develop standardized biomarkers. Leading biotechs will discuss their latest clinical updates, mechanistic data, experimental methods, and clinical trial design.

Microbiome Connect will be hosting their annual skin and oral event at the same venue and dates, which all gut attendees will have access to. Download the agenda https://hubs.ly/H0RQsBQ0.